The report, “Global Orphan Drugs Market” analyzes the current prevailing condition of the market along with its future scope of development. The global market along with specific market of the U.S., Canada, Europe and Japan, is being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.
Complete report on Orphan Drugs market spread across 56 pages providing 5 company profiles and 44 charts and 7 tables is available at:
A rare disease is the one that occurs uncommonly or rarely in the general population. However, there exists no clear definition for categorizing “rare diseases” and is usually defined on the basis of the prevalence, and some other factors including the severity of disease and availability of treatment options. Rare diseases are often serious, chronic and progressive. Orphan drugs are medicinal products intended for the diagnosis, prevention or treatment of rare diseases. These drugs are referred to be “orphan” as under normal conditions because these drugs are not cost effective to be developed by the pharmaceuticals industry, intended for a small number of patients suffering from rare conditions.
Increasing sales of prescription drugs, substantial benefits for new entrants in rare disease drug market, increased spending on medicines, rising healthcare expenditure and improving economic conditions of nations are some of the significant factors driving growth of the Orphan drugs market. However, the growth of the market is hindered by certain challenges including tougher regulatory approvals, limitation on charging higher prices and no approved drugs for several rare diseases including Polychethemia Vera (PV).
Place a direct purchase order on this orphan drugs industry report at USD 800 (Single User License):
The global orphan drugs market is expected to see numerous developments including approval of several Ultra-Rare drugs, increasing scope of Gene therapy, development of drugs for rare blood disease, higher success prospects for Hematology compared to Solid Tumors, attractive pricing option for orphan drug competitors and striking opportunities in developing orphan drugs.
Few Points From List of Tables & Charts Provided in Global Orphan Drugs Market:
List of Tables
Orphan Drugs as Proportion of New Molecular Entities Approved in the U.S. (2010-2014)
Orphan Drugs Approved in Japan (2014)
Prices and Prevalence of Orphan Drugs in the U.S
Current Ongoing Trials for Rare Blood Diseases
Recently Approved Ultra-Orphan Drugs
Globally Operating Top Orphan Drugs Competitor’s Overview
The U.S. Orphan Drugs Competitor’s Overview (2014)
List of Charts
Global Orphan Drugs Market (2010-2015E)
Orphan Drugs as Percent of Prescription Drugs (2010-2015E)
Global Orphan Drugs Market by Type (2014)
Average Cost per Patient for Orphan & Non-orphan Drugs (2010-2014)
Median Cost per Patient for Orphan & Non-orphan Drugs (2010-2014)
Non-Hodgkin’s Lymphoma Stage at Diagnosis (2014)
Non-Hodgkin’s Lymphoma (NHL) by Sub-Types (2014)
Incidence of Non-Hodgkin’s Lymphoma in Major Countries (2010-2014)
Orphan Drug (OD) Applications & Designations per Year (2009-2014)
The U.S. Orphan Drugs Spending (2009-2014E)
The U.S. Orphan Drugs Spending Forecast (2015-2018)
Prevalence of LEMS in the U.S. (2015-2020E)
Firdapse Drug’s Sales and Penetration Rate (2015-2020E)
The U.S. Epilepsy, Tourette and West Syndrome Prevalence (2015-2020E)
The U.S. CPP-115 Revenue (2018-2022)
Explore more pharmaceuticals market research as well as other newly published reports by Koncept Analytics at:
MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers.
Get in touch with us for your needs of market research reports.
Company Name: Market Reports Online
Contact Person: Ritesh Tiwari
Email: Send Email
Phone: +1 888 391 5441
Address:UNIT No. 802, Tower no. 7, SEZ, Magarpatta city, Hadapsar